BusinessStartup Editas plans to test IPO market for biotechs By Robert Weisman — Boston GlobeJan. 4, 2016 Reprints Handout photo of CEO Katrine Bosley Startup Editas plans to test IPO market for biotechs About the Author Reprints Robert Weisman — Boston Globe [email protected] @GlobeRobW Tags biotech genetics startups
Biotech Bob Herman and Damian Garde STAT Plus: Moderna CEO made $398 million in 2022, but still pledges to give most to charity
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
Business Bob Herman and Casey Ross STAT Plus: Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
Special Report Jason Mast, Allison DeAngelis and Megan Molteni STAT Plus: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools